Replies to post #9929 on Mast Therapeutics, Inc. (MSTX)

[biopharm]

Ph. III Data not till 2013 I believe... the good news is the amount of cash on hand and maybe we will see some interest from other BP's

No matter if we partner/buyout or move along thru Phase III ... its worth more than the current levels we sit idling at

[biopharm]

looks like we were thinking phase III news just at the right time! First... this is positive that it seems to show that phase III was accepted by the FDA and all is a go to move forward.

Should bring us between $1-2 during the trial.... and maybe even spike to $3 towards the end of the trial awaiting trial data.

I'll be happy with landing over a $1 for the time being